15 sold in the last 24 hours

Order in 0h 0min for same-day shipping

98.9% Purity Verified

Third-Party Tested by Verum Analytics• HPLC-UV/MS

Batch: BIL-CJCND-01-2603Mar 7, 2026

Peptide Secretagogue Analogs

CJC-1295 No DAC

Name: CJC-1295 No DAC
Brand: BioInfinity
SKU: cjc-1295-no-dac
Availability: InStock
Rating: 4.0 (1 reviews)

GHRH analog (Modified GRF 1-29) that stimulates natural, pulsatile growth-hormone release.

$45.00

98.9% Purity Verified

Third-Party Tested by Verum Analytics• HPLC-UV/MS

Batch: BIL-CJCND-01-2603Mar 7, 2026

+99% Purity

Third-Party Tested

COA Available

15 sold in the last 24 hours

Order in 0h 0min for same-day shipping

Select Size

Buy More, Save More

QuantityPrice

Quantity

Add 2 more for 15% off

$45.00

Albert's Verdict

Without the DAC modification, CJC-1295 delivers a sharper, more physiological pituitary pulse — the half-life stays closer to endogenous GHRH patterns. Useful when research design calls for pulse rather than sustained elevation.

View COA

✓ In stock - Ships same day

Arrives as lyophilized (powder) form

Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.

Secure Checkout256-bit SSL

Same-Day DispatchOrder by 2PM EST

Free ShippingOn orders over $200

99%+ Purity3rd-party HPLC

Sterility & EndotoxinsPASSED — every lot

Money-Back Guarantee30-day return window

Researchers also added

Research profile

Long-acting GHRH-receptor analog (no-DAC variant)

A 29-residue growth-hormone-releasing hormone analog (also known as tetrasubstituted GRF 1-29 / mod-GRF 1-29) characterised in the primary literature as a GHRH-receptor agonist with amino-acid substitutions at positions 2, 8, 15, and 27 that reduce enzymatic cleavage. For laboratory characterisation only.

NonpolarPolarPositiveNegativeAromaticCys

29-residue schematic

Molecular formula

C152H252N44O42

Molecular weight

3367.90 g/mol

Sequence length

29 residues

Physical form

Lyophilized powder

Documented purity

≥99% (HPLC)

Research use onlyPubChem CID 16137828 ↗

Mechanism of action

Receptor engagement in the primary literature

Binding and functional-assay data for CJC-1295 No DAC, from peer-reviewed in-vitro pharmacology publications. Values are receptor activity parameters — not clinical outcomes.

GHRHR

Growth-hormone-releasing hormone receptor

EC₅₀ 0.4 nM

Full agonist (in vitro)

In-vitro cAMP assays in HEK-GHRHR cells report full agonism at the GHRH receptor. The 4 amino-acid substitutions vs native GHRH(1-29) are described as reducing DPP-IV degradation and extending in-vitro stability.

Source: Alba et al., JCEM 2006

Receptor EC₅₀ values from in-vitro cAMP functional assays reported in peer-reviewed literature. In-vitro / preclinical characterisation only — no clinical or therapeutic claim is expressed or implied. Research use only.

Study framework

Investigational context

Study designs referencing this compound in the published literature. Descriptions cover framework only — phase, participant count, duration, and citation — not outcomes. Click a card to review the source directly.

Pharmacokinetic Phase 1

Ascending-dose PK/PD in healthy adults

Teichman et al., JCEM 2006

Structural pharmacology

In-vitro receptor binding + stability characterisation

Alba et al., JCEM 2006

Comparative GHRH class

Review of GHRH analog structure-activity

Sackmann-Sala et al., Endocrinology 2015

Independent COA

≥99% purity · <0.05 EU/mL endotoxin · lot-specific

Freedom Diagnostic (accredited)

Compound comparison

Chemistry comparison — growth-hormone secretagogue peptides

Two peptide research compounds published as growth-hormone-secretagogue-family molecules with distinct receptor targets. Reference chemistry only.

Compound	Sequence	MW	Half-life (lit.)	Reference
Ipamorelin peptide	5 residues	711.85 g/mol	~2 hours (lit.)	Raun Eur J Endocrinol 1998
CJC-1295 (no-DAC) peptide	29 residues	3367.9 g/mol	~30 min (lit.)	Alba JCEM 2006

Reference chemistry only. Receptor-binding indications are qualitative (compound engages / does not engage the receptor in in-vitro assays as reported in the cited literature). No comparative-effectiveness claim is expressed or implied.

Cited sources

Peer-reviewed literature

Independent published research indexed from PubMed and peer-reviewed journals — not BioInfinity claims.

[1]PubMed

Sustained-release GH releasing factor (CJC-1295) for hormone studies

2006 · J Clin Endocrinol Metab

View source

[2]PubMed

Effects of CJC-1295 in human GH-deficient adults

2006 · J Clin Endocrinol Metab

View source

[3]PubMed

GHRH analogs and growth hormone pulsatility

2012 · Endocr Rev

View source

For research use only.

Not for human or veterinary use. All data on this page reflects chemistry attributes, in-vitro pharmacology, and study-framework metadata from published peer-reviewed literature. No statement describes or implies any therapeutic effect in humans. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.

Product Description

What CJC-1295 without DAC (Mod GRF 1-29) is

CJC-1295 without DAC (Mod GRF 1-29) is a synthetic 29-amino acid GHRH analog (tetrasubstituted). Mod GRF 1-29 is a tetrasubstituted GHRH analog (Ala2, Gln8, Ala15, Leu27) with ~30-minute half-life (vs ~7 min native GHRH) due to DPP-IV resistance. Lacking DAC's albumin binding, it produces acute pulsatile GH release mimicking physiology, synergizing with GHRPs via complementary cAMP/Ca2+ pathways. It has a molecular formula C152H252N44O42, mass 3367.95 Da. Common synonyms in the literature include Mod GRF 1-29, Modified GRF, and CJC-1295 no DAC.

What it's studied for

Investigation of CJC-1295 without DAC (Mod GRF 1-29) to date is primarily preclinical, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing CJC-1295 without DAC (Mod GRF 1-29) spans Structure-activity research: Studies established that Ala2 substitution prevents cleavage by dipeptidyl peptidase IV (DPP-IV), the primary GHRH-degrading enzyme. The other substitutions (Gln8, Ala15, Leu27) further enhance stability without compromising receptor binding, Combination research: Preclinical and anecdotal studies suggest GHRH + GHRP combinations produce synergistic GH release. The distinct signaling pathways (cAMP vs. calcium) converge on somatotrophs to amplify secretion beyond additive effects, and Pulsatility preservation: Unlike CJC-1295 DAC, the short half-life of Mod GRF 1-29 allows discrete GH pulses when administered 2-3 times daily. This mimics normal physiological secretion patterns more closely than sustained-release compounds. Proposed mechanisms in the literature include GHRHR full agonism: binds pituitary GHRH receptor, triggering Gs-protein coupling and adenylyl cyclase and cAMP/PKA pathway: adenylyl cyclase → cAMP → PKA activation → GH gene transcription and vesicle release. None of this material describes therapeutic outcomes in humans, and BioInfinity does not sell, market, or provide dosing guidance for CJC-1295 without DAC (Mod GRF 1-29) outside laboratory research.

Laboratory handling — storage and reconstitution

Lyophilized CJC-1295 without DAC (Mod GRF 1-29) arrives as a fluffy off-white solid inside a sealed sterile vial. Because it ships as a lyophilized research compound (3367.95 Da), the powder is best stored between 2–8 °C prior to reconstitution and returned to −20 °C in aliquots for long-term storage post-reconstitution. Reconstitution is typically performed with bacteriostatic water (0.9 % benzyl alcohol preserved) rather than sterile water because the preservative extends solution stability once the vial has been punctured. Warming the reconstituted solution to room temperature before drawing helps redissolve any peptide that has settled against the vial wall. Avoid repeated freeze–thaw cycles: for peptides in this molecular-weight range (3367.95 Da), freeze–thaw stress is one of the most common causes of loss-of-purity between batches.

How this batch is verified

Every batch of CJC-1295 without DAC (Mod GRF 1-29) ships with a batch-specific Certificate of Analysis produced by an ISO-accredited third-party analytical laboratory. Reversed-phase HPLC confirms the assay against the expected 3367.95 Da mass (C152H252N44O42); mass spectrometry validates the exact monoisotopic mass; endotoxin (LAL) testing confirms bacterial-contamination limits appropriate for laboratory research; and residual-solvent panels confirm the manufacturing pipeline. The lot number on the outer label matches the COA on the public /coa-library page — every purity claim is independently verifiable before you open the vial.

Related research

For the full mechanistic profile, published references, and constraint notes on CJC-1295 without DAC (Mod GRF 1-29), see the CJC-1295 without DAC (Mod GRF 1-29) research page. All references cited on that page are peer-reviewed primary literature.

Research use only. CJC-1295 No DAC is sold strictly for in-vitro and animal research. It is not a drug, food, supplement, or cosmetic and is not intended for human or veterinary consumption. No statements on this page describe or imply any therapeutic effect.

Technical Specifications

Molecular Formula: C152H252N44O42
Molecular Weight: 3367.97 g/mol
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Customer Reviews

Verified research purchases

5.0(7 reviews)

Matt S.Verified

1 week ago

My go-to source now

After trying a few different suppliers, I've settled on BioInfinity. The quality and service are consistently excellent. Highly recommend.

45 people found this helpful

Chris N.Verified

2 weeks ago

Verifiable quality

The ability to verify the COA on the testing lab's website is huge. This transparency sets BioInfinity apart from other suppliers.

52 people found this helpful

Nicole T.Verified

1 month ago

Reliable and trustworthy

I needed a reliable source with good documentation. BioInfinity delivered on all fronts. Will definitely order again.

38 people found this helpful

Susan M.Verified

3 weeks ago

Great customer service

Had questions about reconstitution and storage. The support team responded quickly with helpful answers. Great experience.

27 people found this helpful

Tony K.Verified

6 weeks ago

Bulk discounts are great

The quantity discounts make this more affordable than other options. Quality is top notch and shipping is fast. Win-win.

41 people found this helpful

Eric W.Verified

2 months ago

Quality you can trust

The COAs and third-party testing documentation give me confidence. This is what professional suppliers should look like.

58 people found this helpful

Diana L.Verified

4 weeks ago

Best value around

When you factor in quality, documentation, and service, BioInfinity offers the best value. I've tried others - this is my standard now.

33 people found this helpful

Frequently Researched Together

Commonly studied alongside in laboratory settings

Bundle total (3 items):$107.00

Research FAQ — CJC-1295 No DAC

Frequently asked questions about this compound for laboratory researchers.

What is CJC-1295 No DAC and how is it different from CJC-1295 DAC?+

CJC-1295 No DAC (also referred to as Mod GRF 1-29) is a short-acting GHRH analog studied for pulsatile GH-release research. Published literature differentiates it from the DAC variant, which carries a Drug Affinity Complex extending serum half-life into days.

Cited: PMID 16384879, PMID 22148949

What is the reported half-life of CJC-1295 No DAC?+

Published pharmacokinetic data describe CJC-1295 No DAC as having a short serum half-life — commonly cited at approximately 30 minutes — supporting research models of pulsatile GHRH stimulation.

Cited: PMID 22148949

Is CJC-1295 No DAC frequently studied alongside Ipamorelin in research?+

Research literature describes CJC-1295 No DAC and Ipamorelin in combined-protocol studies because they target complementary pathways — GHRH-receptor agonism and ghrelin/GHS-R agonism respectively. See our /buy/cjc-1295-ipamorelin product for the pre-blended research vial.

How should CJC-1295 No DAC be stored?+

Lyophilized vials store at −20 °C protected from light. Reconstituted with bacteriostatic water, store at 2–8 °C and use within 30 days. Refer to your COA.

Published research references

Peer-reviewed literature relevant to CJC-1295 No DAC research. Linked PubMed IDs open the original source.

[1]Sustained-release GH releasing factor (CJC-1295) for hormone studies — J Clin Endocrinol Metab (2006) · PMID 16384879
[2]Effects of CJC-1295 in human GH-deficient adults — J Clin Endocrinol Metab (2006) · PMID 16352683
[3]GHRH analogs and growth hormone pulsatility — Endocr Rev (2012) · PMID 22148949

Reviewed by the BioInfinity Research Team

Content reviewed by our research and quality team — biochemistry-degreed reviewers working alongside our analytical lab partner (Janoshik Analytical). Every product page is cross-checked against the cited peer-reviewed literature and the current batch's third-party COA.

For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.

Verified reviews — CJC-1295 No DAC

1 verified buyer

★★★★★

4.0 / 5

James K.Verified buyer

Jun 11, 2026

★★★★★

research is going well

My guinea pig has lost a lot of belly fat

Reviews are submitted by verified buyers via per-order tokenized links. Reviews are evaluated for product-focused content; any review containing therapeutic claims (cured, treats, healed, etc.) may be edited or hidden to maintain compliance with FDA and platform guidelines.

Learn More About This Peptide

Browse All Peptide Research →Research Guides & Protocols

Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.

Research summary

CJC-1295 without DAC (Mod GRF 1-29) — clinical & mechanistic profile

Mod GRF 1-29 is a tetrasubstituted GHRH analog (Ala2, Gln8, Ala15, Leu27) with ~30-minute half-life (vs ~7 min native GHRH) due to DPP-IV resistance. Lacking DAC's albumin binding, it produces acute pulsatile GH release mimicking physiology, synergizing with GHRPs via complementary cAMP/Ca2+ pathways.

Research status

preclinical

Molecular weight

3367.95 g/mol

Molecular formula

C152H252N44O42

Studied applications

•Preserved pulsatility: ~30 min half-life produces discrete GH spikes mimicking physiological patterns
•DPP-IV resistance: Ala2 substitution blocks primary degradation enzyme, extending duration from ~7 to ~30 min
•GHRP synergy: cAMP pathway (GHRH) + Ca2+/IP3 pathway (GHRPs) produce amplified GH pulses beyond additive effects
•Flexible protocols: short duration allows timing with natural GH windows (sleep, exercise)
•No albumin binding: lacks DAC moiety, enabling rapid clearance and pulsatile administration

Mechanisms of action

•GHRHR full agonism: binds pituitary GHRH receptor, triggering Gs-protein coupling and adenylyl cyclase
•cAMP/PKA pathway: adenylyl cyclase → cAMP → PKA activation → GH gene transcription and vesicle release
•DPP-IV resistance: Ala2 substitution blocks dipeptidyl peptidase IV cleavage site
•Synergistic signaling: complements GHRP Ca2+/IP3 pathway for amplified somatotroph activation
•Dose-dependent peaks: produces sharp GH spikes 15-60 min post-injection, baseline by 180 min

Research constraints & safety notes

•Not approved for human therapeutic use
•Short half-life requires 2-3 daily injections for meaningful effects
•No completed human clinical trials for this specific compound
•Quality and purity of research compounds varies
•Optimal dosing and timing protocols not established

Peer-reviewed references

CJC-1295 pharmacokinetic studies (2006)PMID: 16352683View
GHRH analogs and pituitary functionPMID: 2699646View
Wikipedia — CJC-1295 structure and modifications
Paragon Sports Medicine — Mod GRF 1-29 mechanism review

Read the full CJC-1295 without DAC (Mod GRF 1-29) research page View public COA library

For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.

Researchers looking at this often also study

Full catalog

Includes this compound

CJC-1295 & Ipamorelin Blend

View product

Same research area — GH-axis research

IGF-1 LR3

View product

Same research area — GH-axis research

Ipamorelin

View product